Loading patent…
AssigneeCity of Hope
InventorsJavier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, David H. MULAMA, Murali MUNIRAJU
Estimating the term…
Disclosed are vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/rl or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.
A single Kaposi sarcoma-associated herpesvirus-like particle (KSHV-LP) comprising two or more KSHV glycoproteins or an immunogenic fragment thereof.
A vaccine composition or a pharmaceutical composition comprising a therapeutically effective amount of a single KSHV-LP comprising two or more KSHV glycoproteins and one or more T cell antigens.
An expression system for co-expressing two or more KSHV envelope glycoproteins including a single vector inserted with two or more nucleic acid sequences that encode two or more KSHV envelope glycoproteins, linked by one or more linking sequences, such that the two or more KSHV envelope glycoproteins can be co-expressed simultaneously, self-cleaved and/or self-processed to assemble into one or more glycoprotein complexes.
Dependencies are inferred from the claim text.